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ESTABLISHMENT AND CHARACTERIZATION OF NEW BREAST 
AND OVARIAN CANCER CELL LINES AS A MODEL FOR STUDYING 
CELLULAR PLASTICITY IN VITRO
N. Bezdieniezhnykh*, A. Lykhova, N. Semesiuk, R. Okhrimenko, Yu. Kudryavets
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine
Aim: To compare biological properties of primary tumor cells isolated from malignant effusion of cancer patients with the same 
cells of permanent lines established during their long-term cultivation in vitro and to assess the impact of phenotypic conversion 
that was caused by changes in their microenvironment on their behavioral characteristics. Materials and Methods: The study was 
performed on primary cell cultures from pleural effusion or ascites of breast and ovarian cancer and permanent cell lines derived 
from them, namely permanent ovarian cancer cell line I, permanent ovarian cancer cell line II and permanent breast cancer cell line I. 
Biological characteristics were studied using standard cell culture methods and immunocytochemical assays. Results: Three new 
cell lines were established from breast and ovarian cancer and cell morphology, migration activity, the kinetics of growth, colony 
forming activity in semisolid agar and sensitivity to anticancer drug were examined. These characteristics were compared with 
those of the primary tumor cells. It has been shown that among the primary tumor cells from malignant effusion, cells with mese-
nchymal characteristics were the most prevalent. Cultivation of primary cancer cells in vitro leads to a phenotypic change of their 
population: it becomes more homogeneous in morphology with predominantly epithelial-like cells. Also, later after a number of cell 
doublings in vitro, the cell population changes to include cells primarily with immunophenotypic properties characteristic of epi-
thelial cells. These changes include increase in number of E-cadherin-positive cells and a decrease in number of vimentin and α- 
smooth muscle actin-positive cells. It was found that significant changes in expression of epithelial-mesenchymal transition associ-
ated proteins in cells during their cultivation in vitro in new microenvironment are accompanied by a rapid change in their sensiti-
vity to anticancer drugs. Conclusions: The new breast and ovarian cancer cell lines were established and characterized. The induc-
tion of phenotypic transdifferentiation in malignant cells from pleural effusion and ascites can be an important approach for sup-
pressing the progression of neoplastic process.
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Cell lines as pharmacogenomics models have the 
following advantages: they are easy to culture, rela­
tively inexpensive, and amenable to testing of various 
therapeutic agents. Data generated from cell lines 
can then be used to link cellular drug response to ge­
nomic and proteomic features, where the ultimate goal 
is to build predictive signatures of patient outcome. 
Despite decades of improvements in methods for 
establishing cancer cell lines it is extremely difficult 
to routinely establish “quality” permanent cell lines 
from human primary tumors with high efficiency, limi­
ting the number and diversity of cell lines available 
for study. Additionally, in many types of tumors, only 
specific subtypes of cells from a tumor biopsies yield 
a viable cell line and this has resulted in availability 
of a collection of cell lines that do not accurately re­
flect the true heterogenic spectrum of tumor cells 
in neoplasia and tumors encountered in the clinic; 
at the same time, the original tumor is not available for 
analysis with the modern technologies [1]. Therefore, 
it is important to develop more effective platform for 
drug investigation with a more efficient method of es­
tablishing human tumors as cultures that reflect the 
heterogeneity of human malignancies. The critical 
first step in the pre­clinical cascade of cancer drug 
discovery depends almost entirely on the use of in vitro 
models, however, in vitro models of human cancers 
that are currently used in cancer biology and drug 
discovery do not incorporate complexity or heteroge­
neity of tumors [2]. Cancer is a complex and hetero­
geneous pathological growth that continuously and 
dynamically interacts with its host. Among the different 
phenotypic properties acquired by cancer cells during 
tumor progression markers of epithelial­mesenchymal 
transition (EMT) have been extensively described. EMT 
allows an epithelial polarized cell to acquire a more 
mesenchymal phenotype with increased mobility and 
invasiveness. In the neoplastic context in many tumors 
EMT is associated with a more aggressive tumor phe­
notype including local invasion and distant metastasis. 
Despite the fact that many EMT markers have been as­
sociated with poor disease prognosis in different stu­
dies and, while an EMT phenotype seems to be clearly 
associated with an increased metastatic phenotype, 
the use of such markers has not yet been translated 
into clinical practice. Any prognostic markers should 
be reproducible among different laboratories and have 
to display great robustness. EMT markers have not yet 
been used in clinical practice for several reasons and 
tumor heterogeneity is one of the main reasons [3]. 
Such heterogeneity can be the result of cell intrinsic 
genomic differences or interaction with the microen­
vironment [4]. Investigations into the role of the tumor 
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microenvironment and the mechanisms of stromal cell 
recruitment have also provided insights into a distinct 
aspect of tumor biology: cancer progression may 
also be directed by the systemic responses of orga­
nism to malignancy and by the involvement of organ 
systems located at sites distant from primary tumor. 
Many of the factors have dual or ambivalent roles [5]. 
Dissemination of tumor cells in abdominal or pleu­
ral cavities as ascitic form or cancer pleural effusion 
is the indicator of poor prognosis in cancer patients: 
the spread of the tumor cells to the ascites has been 
postulated to play a dominant role in metastasis, che­
moresistance and, ultimately, an incurable disease. 
Ascitic form of cancer differentially triggers a dis­
semination phenotype related to the initial cell features 
by either allowing the proliferation and the formation 
of sphe roids and the extension of colonies for cells that 
present an initial epithelial intermediate phenotype, 
or favoring the migration of cells with a mesenchymal 
intermediate phenotype. There are data that ascites 
induces a shift toward an unstable intermediate state 
of the epithelial­mesenchymal spectrum and confers 
a more aggressive cell behavior that takes on a different 
pathway based on the initial epithelial­mesenchymal 
cell features. A thorough understanding of the biology 
of the ascites microenvironment is essential for deve­
loping effective therapeutic intervention for metastatic 
ovarian, breast, lung and many other cancers. Cancer 
cell lines, originally isolated from ascites, are readily 
available, immortalized, highly autonomic and provide 
a low­cost option to assess tumor cell behavior [6].
Heterogeneity of metastatic cancer cell population 
is one of the reasons why some patients are more respon­
sive to some treatments over others. EMT, while favoring 
the formation of more metastatic cancer cells, also pro­
vides signals for increasing survival which may cause drug 
resistance in some if not all the cells present in a tumor. 
Since this is a very complex and dynamic mechanism, 
thorough investigation is necessary to fully understand 
the mechanism of drug action and drug resistance [7].
MATERIALS AND METHODS
Primary cell cultures. Ascites or pleural effusion 
were collected at the time of paracentesis for palliative 
reasons from patients with ovarian cancer and breast 
cancer. The cell biomass was separated from the 
cancer effusion and placed into 75 cm2 tissue culture 
flasks (TPP, Italy) in culture medium RPMI­1640 (PAA, 
Austria) supplemented with 15% fetal bovine serum 
(FBS) (PAA, Austria) and 40 mg/ml gentamicin (Sigma, 
USA). Flasks were incubated at 37 °C and with 5% CO2. 
The medium was removed after 3–4 days and replaced 
with fresh RPMI­1640 medium supplemented with 
15% FBS, 2 mM L­glutamine, 40 mg/ml gentamicin. 
Subsequently, the media was replaced twice a week.
Permanent cell lines. The human breast cancer 
and ovarian cancer cell lines designated as BCC/
Permanent (BCC/P) and OCC/Permanent II (OCC/PII), 
respectively were maintained in RPMI­1640. Human 
ovarian cancer cell line OCC/Permanent I (OCC/PI) 
was cultured in DMEM. All media were supplemented 
with 10% FBS and 40 mg/ml gentamicin. The cells 
were incubated at 37 °C in a humidified atmosphere 
with 5% CO2. Cells were detached with EDTA solu­
tion (Sigma, USA) using standard method [8]. All 
permanent cell lines were placed in collection of the 
Bank of Cell Lines from Human and Animal Tissues 
of R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology of the National Academy 
of Sciences of Ukraine.
Study of cell morphology. The flasks with BCC/P, 
BCC/Primary (BCC/Pr), OCC/PI, OCC/Primary I (OCC/
PrI), OCC/PII and OCC/Primary II (OCC/PrII) cells 
were viewed in inverted microscope Axiovert 25 (Carl 
Zeiss, Germany) equipped with digital camera (Canon 
Power Shot A640, UK) at 100–320­fold magnification. 
The cultures of live cells were photographed and the 
ima ges were analyzed using Shortcut to Remote Capture 
software. Additionally, cells were stained using standard 
methods with Romanowsky — Giemsa stain [8]. Stained 
slides were photographed and the images were analyzed.
Growth kinetics of tumor cells. All experiments 
were initiated using stock cultures maintained in expo­
nential phase of growth. Cells (1•104/ml) were seeded 
in 24­wells plate in 1 ml of DMEM or RPMI­1640 medi­
um supplemented with 10% FBS and 40 mg/ml genta­
micin. The cells were incubated at 37 °C in a humidified 
atmosphere with 5% CO2 for 7 days. Every day cells 
were detached with EDTA solution from three wells 
at each time point, stained with trypan blue solution 
(HyClone, USA) and counted using hemocytometer. 
All experiments were repeated twice.
Semisolid agar colony assay. The assay was 
conducted in parallel wells in 6­well plates. Base la­
yers of 3 ml of 0.5% agar (Difco, USA) were prepared 
on RPMI­1640 medium with 10% FBS. A 1 ml overlayer 
of 0.33% agar containing BCC/P, OCC/PII or OCC/
PI cells (5•103) in RPMI­1640 medium with 10% FBS and 
40 mg/ml gentamicin was then applied and the plates 
were incubated at 37 °C in a humidified atmosphere 
containing 5% CO2. After 14 days of the incubation, 
the plating colonies were stained with 0.2% solution 
of methylthiasoliletetrazolium (Sigma, USA) at 37 °C for 
3 h. After that, the number of colonies was counted 
in each well using binocular magnifier BM­51­2 (LOMO, 
Russia). Images of live colonies were acquired on the 
inverted microscope Axiovert 25 equipped with a digital 
camera. Colony­forming activity (CFA) of these cells 
was determined using the formula: 
CFA = (A/B) • 100%, 
wherein A — the number of colonies per well; B — 
the number of cells plated in semisolid agar per well.
Migration assay. The BCC/P, OCC/PI and OCC/
PII cells (1•105/ml) were seeded in 12­well plates (TPP, 
Italy) in DMEM or RPMI­1640 complete medium and 
incubated at 37 °C in a humidified atmosphere with 5% 
CO2 until cells reach 100% confluence to form a mono­
layer. We used a p200 pipet tip to create a scratch 
in the cell monolayer. In each well the medium was 
changed to remove debris and to smooth the edges 
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of the scratch. After that, the migration of cells across 
the “scratch” was photographed with phase contrast 
microscope. The first image was made 3 h later and 
the following images were taken at intervals of 6 h. The 
images were analyzed and the time required to close 
the scratch was determined [9].
Immunocytochemical assay. The phenotype 
of BCC/P, OCC/PI and OCC/PII cells was determined 
by immunocytochemical staining with monoclonal 
antibodies against E­cadherin, Vimentin, α­sm­actin 
(Thermo Scientific, USA) and N­cadherin (BioLegend, 
USA). Cells were grown on coverslips for 48 h and ana­
lyzed using standard method [10]. For visualization, Ultra 
Vision LPValue Detection system was used. DAB Quanto 
(3,3­diaminobenzydyne; Thermo Scientific, USA) was 
used as a chromogen. Immunocytochemical reactions 
were assessed semiquantitavely using H­score account­
ing for the proportion and intensity of the stained cells. 
The percentage of the stained cells was multiplied by the 
score number corresponding to the staining intensity (0 = 
none, 1 = weak, 2 = moderate, 3 = strong). The resulting 
score ranged from 0 (no stained cells) to 300 (diffuse 
intense staining of cells), and H score was calculated as 
(% of cells stained at intensity 1 × 1) + (% of cells stained 
at intensity 2 × 2) + (% of cells stained at intensity 3 × 3). 
H­score between 0 and 300 was obtained where 300 cor­
responded to 100% of intense staining [11].
Sensitivity to the anticancer drugs. All ex­
periments were initiated using stock cultures main­
tained in exponential phase of growth. Cell suspen­
sions (1•104 cells/ml) were seeded into 96­well 
culture plates, 100 ml per well and incubated for 
24 h at 37 °C. Then the medium was replaced with 
fresh medium containing different concentrations 
of anticancer drugs: fluorouracil, platinum and camp­
tothecin. Plates were incubated for 72 h at 37 °C and 
5% CO2. Cells were counted by colorimetric assay with 
crystal violet [12]. All experiments were performed 
in triplicate and the results were expressed as inhibi­
tory rate (IR):
IR = (1–A540 (experiment)/A540 (control))•100%.
Statistical analysis. Statistical data processing 
was performed by the Student t­test using Statis­
tica 6.0 computer program (StatSoft Inc., USA).
RESULTS AND DISCUSSION
In order to better understand the behavior of can­
cer cells in vitro we investigated certain biological 
characteristics of these cells, such as EMT signature 
and sensitivity to anticancer drugs, under conditions 
permissive to phenotypic plasticity. We derived two 
permanent cell lines from ovarian cancer ascites 
(OCC/PI and OCC/PII) and one cell line from breast 
cancer pleural effusion (BCC/P). Morphological 
analysis of primary cell lines obtained from pleural 
fluid of the patient with breast cancer BCC/Pr showed 
that cell population consisted mainly of two types the 
cells, round shaped and elongated fibroblasts (which 
constitute the majority of cell population) with small 
number of polygonal cells (Fig. 1).
We obtained the permanent BCC/P cell line from 
primary cell line BCC/Pr by long­term passages in vitro 
(more than 20–30 cell divisions). The study of mor­
phological features of BCC/P cells showed that they 
formed a homogeneous culture of cells smaller than 
the BCC/Pr cells with mainly epithelial­like morpho­
logy (Fig. 1, d, e).
From primary cell lines from ovarian cancer ascites 
(OCC/PrI and OCC/PrII) we obtained 2 permanent cell 
lines — OCC/PI and OCC/PII by long­term passages 
in vitro more than 20–30 cell divisions (Fig. 2).
The study of morphological features of cell lines 
derived from ovarian cancer showed that the primary 
culture OCC/PrI is heterogeneous and contains adher­
ent cells with fibroblast­like morphology and cells that 
are substrate independent and grow in suspension 
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Fig. 1. The morphology of primary BCC/Pr cells (a–c) and a permanent BCC/P cell line (d, e): live cells (a, b, d, e), cytological 
preparation (stained by Romanowsky — Giemsa (c)). × 100 (a, d), × 320 (b, e), × 400 (c)
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(Fig. 2, a–c). Permanent cell line OCC/PI is charac­
terized by homogeneity of the population that grows 
as a substrate dependent culture and acquires mor­
phology similar to epithelial cells.
Morphological analysis of primary cell lines OCC/
PrII revealed that primary cell cultures formed “cell 
islands” consisting of big epithelial­like cells with large 
vacuoles (Fig. 2, d–f). In addition, we observed a sig­
nificant number of typical epithelial cells that form the 
structure of “cobblestone” type. Through 30–40 cell 
doublings we obtained the permanent cell line OCC/
PII that consists from two cell types: smaller­sized cells 
that form the epithelial islands and large cells (more 
than 100–200 micrometers) with 1 or 2 nuclei (Fig. 2, j).
Analysis of the kinetics of growth of derived perma­
nent cell lines revealed a significant difference in their 
growth characteristics: cells of BCC/P line quickly 
reached the maximum number (4 days) and entered 
the plateau phase of the rapid aging of the cell culture 
and reduction in the number of live cells; whereas cells 
of OCC/PI and OCC/PII lines grew slowly with a gradual 
doubling of the cells (Fig. 3).
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Fig. 3. Kinetics of growth of permanent cell lines derived from 
pleural effusion or ascites of patients with breast and ovarian cancer
b c
f
a
j ki
ed
hg
Fig. 2. Morphology of primary ovarian cancer OCC/PrI (a–c) and OCC/PrII (d–f) cells and OCC/PI (g, h), OCC/PII (i, j, k) cell lines: 
live cells (a, b), cytological preparation (stained by Romanowsky — Giemsa (c, f, k)). × 100 (a, d, g, i), × 320 (b, e, h, j), × 400 (c, f, k)
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Normal cells need a variety of internal and external 
signals to support their proliferation and differen­
tiation as compared to malignant cells that acquire 
the capa city for autonomous (independent) growth 
through a series of genetic and epigenetic changes. 
It is one of the main features of cellular malignant 
transformation. The ability of tumor cells to form 
colonies in semisolid agar is considered the most ac­
curate method of assessing the “level of malignancy” 
of cells in vitro and correlates with the level of their 
tumorigeni city and metastatic potential in vivo. 
We analyzed the colony forming abi lity of primary 
and permanent cell lines BCC and OCC and showed 
that only BCC/P and OCC/PI are able to form colo­
nies in semisolid agar. This indicates the acquisition 
of certain new biological characteristics by perma­
nent cells when compared to their original source 
as a result of certain selective actions during their 
growth in vitro. Colony forming activity in semisolid 
agar of BCC/P cell line was 8.0 ± 0.1%, OCC/PI — 
3.4 ± 0.7% (Fig. 4). We also calculated the number 
of colonies formed by BCC/P cells of different size: 
17.6 ± 1.6% of large colonies (> 100 cells), 16.4 ± 
0.9% of small colonies (10–30 cells) and 66.0 ± 0.8% 
of medium colonies (30–100 cells).
One of the important parameters of malignancy 
of tumor cells is their ability to migrate. This, together 
with the invasion, are key characteristics of the mani­
festation of “metastatic behavior” of malignant cells, 
such as their ability to proliferate and form second­
ary metastatic lesions. One of the most simple and 
effective methods for analyzing the migration ability 
of tumor cells in vitro is the scratch assay. This method 
can be used to study the mechanisms of regulation 
of cell migration during the interaction of cells be­
tween themselves and with the intercellular matrix 
[13]. Therefore, we investigated the cell migration 
activity of BCC/PI and OCC/PI cells using scratch 
assay. OCC/PII was excluded from this analysis be­
cause it failed to consistently reproduce the results 
of the assay. The analysis showed that total time 
of the monolayer restoration for BCC/PI line was 48 h 
(Fig. 5) and for OCC/PI — 60 h. 
Molecular markers of EMT are an important charac­
teristic of tumors. EMT plays an important role in the 
acquisition of mesenchymal characteristics by epithelial 
cells and is associated with an increased invasive and 
migratory ability of cells and the formation of malignant 
metastatic phenotype. In addition, tumor cells chara­
cterized by predominantly mesenchymal markers are 
less sensitive to anticancer drugs and therefore consti­
tute a resistant phenotype [14–16]. It has been shown 
that increase in E­cadherin expression (epithelial cell 
marker) is associated with increased sensitivity of re­
b ca
Fig. 4. Colonies of BCC/P cells of different size in semisolid agar: a — small (10–30 cells), b — medium (30–100 cells), c — large 
(> 100 cells)
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Fig. 5. Migration activity of the BCC/PI (I) or OCC/PI (II) cells: a, d — 3 h; b, e — 24 h; c, f — 48 h after damage of their monolayer
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sistant human lung cancer cells (with mesenchymal 
characteristics) to inhibitor of epidermal growth factor 
receptor [14]. In addition, it has been reported that tu­
mor cells with mesenchymal phenotype have a “protec­
tive effect” from DNA­damaging antineoplastic factors 
at the level of Zeb2/SIP1 expression, which is inversely 
correlated with the expression of E­cadherin [17]. Re­
cently, cancer stem cells have been shown to be resis­
tant to anticancer drugs and it was suggested that the 
occurrence of cancer stem cells is partly a consequence 
of EMT [18, 19]. 
This led us to investigate some EMT markers 
in primary versus permanent cells of BCC and OCC 
lines in conditions of their unstable microenvironment: 
after growth in “spheroidal/suspension” conditions 
in ascites and the following in vitro cultivation — the 
substrate “extracellular environment”. We show that 
after a number of cell doublings in vitro cell immu­
nophenotypic characteristics changed to reflect the 
properties of epithelial cells. This includes an increase 
in the number of E­cadherin­positive cells and a de­
crease in the number of vimentin and α­smooth muscle 
actin­positive cells. These changes were especially 
dramatic (and statistically significant) in the breast 
cancer cells (Fig. 6).
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Fig. 6. EMT markers in primary and permanent cell lines of breast 
and ovarian cancer. The level of antigen expression is presented 
in points of H­score system. *Differences in marker expression 
levels in primary cells vs permanent cell line are statistically 
significant (p < 0.05)
The course of prescribed anticancer therapy 
is based on the main phenotypic characteristics of the 
tumor and prevalence of disease. Recent studies 
have focused on finding ways to individualize a choice 
of therapy based on understanding of the mechanisms 
of carcinogenesis and molecular markers. The cells 
from the original tumor and newly formed metastatic 
lesions often differ in sensitivity to chemotherapy. Thus 
it is extremely important to understand the sensitivity 
of tumor cells to chemotherapeutics with different 
mechanism of action during tumor progression and 
phenotypic conversion of tumor cells. We found that 
the sensitivity of primary tumor cells from ascites 
quickly changes after cells are cultured as the perma­
nent cell lines (Fig. 7).
CONCLUSIONS
In conclusion, we have obtained new tumor cell 
lines from pleural effusion and ascites from patients 
with breast or ovarian cancer and described some 
of their growth characteristics, immunophenotype 
features and sensitivity to certain anticancer drugs. 
The results indicate that primary mesenchymal­like 
tumor cells quickly (during 5–10 doublings) transform 
into cells with epithelial phenotype. Also, we have 
established that cells as permanent cell lines lose 
their EMT­signature while their sensitivity to anti­
cancer drugs increases significantly. We found rapid 
transformation and the acquisition of new properties 
in a changing microenvironment (intercellular and 
substrate contacts, soluble factors, etc). This suggests 
that the induction of phenotypic transdifferentiation 
in malignant cells from pleural effusion and ascites 
can be an important approach for suppressing the 
progression of neoplastic process. Our results demon­
strate that change in phenotype of tumor cells causes 
a change in their behavior and, consequently, the ef­
fects of anticancer agents. These results also highlight 
the necessity to further study the association of EMT 
of tumor cells with their response to anticancer agents 
and the importance of monitoring the phenotypic 
plasticity of malignant cells.
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Fig. 7. Half maximal inhibitory concentration (IC50) of antican­
cer drugs with different mechanisms of action for primary and 
permanent cell lines from pleural effusion or ascites of patients 
with breast/ovarian cancer. *Difference in IC50 for primary cells 
vs permanent cell line is statistically significant (p < 0.05)
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